NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

Core Viewpoint - NRx Pharmaceuticals, Inc. is set to release its second quarter 2025 financial results on August 14, 2025, and will host a conference call to discuss corporate and financial updates, including recent regulatory events and operational plans [1][2]. Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [3]. - The company is developing two key products: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone [3]. - NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, while NRX-101 has been granted Breakthrough Therapy Designation for suicidal bipolar depression [3]. Regulatory Developments - NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application (NDA) for NRX-100, seeking to utilize the Commissioner's National Priority Voucher Program for treating suicidal depression [4]. - The NDA filing is based on results from well-controlled clinical trials conducted in collaboration with the US National Institutes of Health and the Government of France [4].